Information Library

Results for: Connect with investigators, regulators and physicians - Europe

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Partnering is Key to Maximizing Rewards in Emerging Markets

    Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.

  • Managed Entry Services

    Brochure — December 20, 2010
    Managed Entry Services from Quintiles pairs an established national team with a powerful combination of unique competencies, rich NHS knowledge and extensive local relationships.

  • QUINTILES ANNOUNCES CLINICAL RESEARCH PARTNERSHIP WITH THE UNIVERSITY MALAYA MEDICAL CENTRE

    Press Release — July 5, 2010 - Quintiles announces a strategic alliance agreement with the University Malaya Medical Centre (UMMC) as part of its unique Prime Site program.

  • Malaysia Prime Site

    Video — July 2, 2010
    Adam Chasse, Sr. Director, Access to Patients explains the importance of Prime Sites and the impact of our clinical research partnership with the University of Malaya Medical Centre in Malaysia.

  • Commercial – Identify, Promote and Prove Treatment Value

    Brochure — April 1, 2010
    Quintiles has built an unmatched suite of commercial competencies that biopharma companies are leveraging for faster market access and sustained success.

  • QUINTILES EXTENDS PHASE I CAPACITY AND CAPABILITIES

    Press Release — March 8, 2010 – Quintiles announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.

  • New FDA Guidance on Antidiabetic Therapies

    White Paper — December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

Page 1 of 1 (7 results)

Subscribe to Email Based on Your Interests

Set preferences